A Phase II Study of YHI-1702 (duvelisib) in Patients with Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Hiroki Kageyama0 个研究点目标入组 21 人开始时间: 2022年3月14日最近更新: 2024年5月27日

试验速览

暂无简介。

•1) Hematocytologically or histopathologically proven ATL with positivity of anti-HTLV-1 antibody
•2) Diagnosed as aggressive ATL (acute type, lymphoma type, or chronic type with unfavorable factor ATL)
•3) Receiving at least one prior systemic therapy including mogamulizumab-containing regimen or, if mogamulizumab-intolerant or contraindication, one or more regimens of systemic therapies excluding mogamulizumab
•4) Must have at least one measurable lesion, or evaluable lesion in either of peripheral blood or skin based on the response criteria defined in this study
•5) ECOG PS of 0 to 1
•6) Written informed consent

•1) Received prior allogeneic transplant, or prior autologous transplant within 12 weeks (84 days) prior to initiation of study treatment
•2) Received prior treatment with PI3K inhibitors
•3) Ongoing treatment for systemic bacterial, fungal, or viral infection
•4) Administration of medications or foods that are strong inhibitors or inducers of CYP3A within 14 days of enrollment

发起方

Hiroki Kageyama